Acumen Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.33 Insider Own15.73% Shs Outstand40.47M Perf Week6.81%
Market Cap139.28M Forward P/E- EPS next Y-0.98 Insider Trans0.00% Shs Float34.12M Perf Month-16.06%
Income-82.70M PEG- EPS next Q-0.26 Inst Own77.90% Short Float5.56% Perf Quarter-39.47%
Sales- P/S- EPS this Y32.00% Inst Trans5.24% Short Ratio8.19 Perf Half Y-65.01%
Book/sh5.34 P/B0.65 EPS next Y-47.00% ROA-43.60% Target Price17.50 Perf Year-
Cash/sh4.68 P/C0.74 EPS next 5Y32.10% ROE-58.20% 52W Range3.02 - 26.98 Perf YTD-48.96%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-87.21% Beta-
Dividend %- Quick Ratio48.80 Sales past 5Y- Gross Margin- 52W Low14.24% ATR0.31
Employees14 Current Ratio48.80 Sales Q/Q- Oper. Margin- RSI (14)43.02 Volatility8.04% 9.55%
OptionableYes Debt/Eq0.00 EPS Q/Q67.70% Profit Margin- Rel Volume0.80 Prev Close3.48
ShortableYes LT Debt/Eq0.00 EarningsMay 16 AMC Payout- Avg Volume231.36K Price3.45
Recom1.50 SMA20-5.69% SMA50-18.99% SMA200-61.79% Volume184,871 Change-0.86%
Jan-21-22Upgrade BofA Securities Neutral → Buy $16 → $14
Jul-26-21Initiated UBS Buy $27
Jul-26-21Initiated Stifel Buy $27
Jul-26-21Initiated Credit Suisse Outperform $26
Jul-26-21Initiated BofA Securities Neutral $20
May-16-22 10:00PM  
May-11-22 05:08PM  
Apr-27-22 08:00AM  
Apr-02-22 12:00AM  
Apr-01-22 05:01PM  
Mar-28-22 04:05PM  
Mar-16-22 04:15PM  
Dec-30-21 04:16AM  
Nov-25-21 07:35AM  
Nov-15-21 08:00AM  
Nov-08-21 08:00AM  
Nov-02-21 08:00AM  
Oct-07-21 08:00AM  
Oct-01-21 06:05AM  
Aug-16-21 04:05PM  
Jul-23-21 07:13PM  
Jul-01-21 05:02PM  
Jun-30-21 10:44PM  
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OConnell Daniel JosephPresident and CEONov 30Option Exercise4.471,1184,9972,685Dec 02 04:41 PM
Manning Paul B10% OwnerJul 06Buy16.00312,5005,000,0003,352,693Jul 08 06:35 PM
Stalfort John A IIIDirectorJul 06Buy16.0035,000560,000172,324Jul 08 06:17 PM
Hardie Robert D.10% OwnerJul 06Buy16.00312,5005,000,0003,352,693Jul 08 06:15 PM
Hardie Robert D.10% OwnerJul 06Buy16.00750,00012,000,0003,951,156Jul 08 06:14 PM
Fountain Nathan BDirectorJul 06Buy16.006,250100,0006,250Jul 08 06:13 PM
Sands Capital Ventures Discove10% OwnerJul 06Buy14.88450,0006,696,0003,417,075Jul 08 05:21 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 06Buy16.001,875,00030,000,0007,881,889Jul 08 04:32 PM